Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell | Phase 1 | Status: WITHDRAWN